胆道癌围手术期化疗的研究进展
摘要
BTC患者被诊断为不可切除或转移性疾病。所有BTC中只有 20%-30%适用于潜在的可切除的疾病。虽然手术切缘阴
性的根治性切除是BTC唯一可能治愈的方法，但大多数患者术后复发，预后较差。因此，围手术期治疗是提高生存
率的必要手段。由于BTC相对罕见，围手术期化疗的随机 III期临床试验很少。在最近的一项ASCOT试验中，与前
期手术相比，BTC切除患者使用 S-1辅助化疗显着提高了总生存率。在东亚地区，S-1目前被认为是标准的辅助化
疗方案，而卡培他滨仍可能在其他地区使用。在一项 III期实验（KHBO1401）表明，吉西他滨和顺铂加 S-1（GCS）
已成为晚期BTC的标准化疗方案。GCS不仅提高了总生存率，而且显示出较高的有效率。在日本的一项随机 III期试
验（JCOG1920）中，研究了 GCS作为可切除BTC术前新辅助化疗的疗效。在这篇综述中，我们总结了目前和正在
进行的针对BTC的辅助和新辅助化疗的临床试验。
关键词
全文:
PDF参考
[1]Valle J W, Kelley R K, Nervi B, et al. Biliary tract
cancer[J]. Lancet, 2021,397(10272):428-444.
[2]Krasinskas A M. Cholangiocarcinoma[J]. Surg Pathol
Clin, 2018,11(2):403-429.
[3]Rizzo A, Brandi G. Adjuvant systemic treatment in
resected biliary tract cancer: State of the art, controversies,
and future directions[J]. Cancer Treat Res Commun,
2021,27:100334.
[4]Rizzo A, Brandi G. Neoadjuvant therapy for
cholangiocarcinoma: A comprehensive literature review[J].
Cancer Treat Res Commun, 2021,27:100354.
[5]Valle J, Wasan H, Palmer D H, et al. Cisplatin plus
gemcitabine versus gemcitabine for biliary tract cancer[J]. N
Engl J Med, 2010,362(14):1273-1281.
[6 ]Mo rizane C, Oku saka T, Mizu sawa J, et al.
Combination gemcitabine plus S-1 versus gemcitabine plus
cisplatin for advanced/recurrent biliary tract cancer: the
FUGA-BT (JCOG1113) randomized phase III clinical trial[J].
Ann Oncol, 2019,30(12):1950-1958.
[7]Ioka T, Kanai M, Kobayashi S, et al. Randomized
phase III study of gemcitabine, cisplatin plus S-1 versus
gemcitabine, cisplatin for advanced biliary tract cancer
(KHBO1401- MITSUBA)[J]. J Hepatobiliary Pancreat Sci,
2023,30(1):102-110.
[8]Bridgewater J, Palmer D, Cunningham D, et al.
Outcome of second-line chemotherapy for biliary tract
cancer[J]. Eur J Cancer, 2013,49(6):1511.
[9]Shindo Y, Nagano H, Kanai M, et al. Clinical
outcomes of secondline chemotherapy after gemcitabine and
cisplatin plus S1 treatment for patients with advanced biliary
tract cancer in the KHBO14013A study[J]. Oncol Rep,
2023,49(2).
[10]Noji T, Hirano S, Tanaka K, et al. Concomitant
Hepatic Artery Resection for Advanced Perihilar
Cholangiocarcinoma: A Narrative Review[J]. Cancers (Basel),
2022,14(11).
[11]Nakahashi K, Ebata T, Yokoyama Y, et al. How long
should follow-up be continued after R0 resection of perihilar
cholangiocarcinoma?[J]. Surgery, 2020,168(4):617-624.
[12]Miyazaki M, Shimizu H, Yoshitomi H, et al.
95
现代医学前沿 | 第2卷/第11期
Advances in Mordern Medical
Clinical implication of surgical resection for recurrent biliary
tract cancer: Does it work or not?[J]. Ann Gastroenterol Surg,
2017,1(3):164-170.
[13]Woo S M, Yoon K A, Hong E K, et al. DCK
expression, a potential predictive biomarker in the adjuvant
gemcitabine chemotherapy for biliary tract cancer after
surgical resection: results from a phase II study[J]. Oncotarget,
2017,8(46):81394-81404.
[14]Siebenhüner A R, Seifert H, Bachmann H, et al.
Adjuvant treatment of resectable biliary tract cancer with
cisplatin plus gemcitabine: A prospective single center phase II
study[J]. BMC Cancer, 2018,18(1):72.
[15 ]T a k a d a T, Am ano H, Y a su d a H, et al. I s
postoperative adjuvant chemotherapy useful for gallbladder
carcinoma? A phase III multicenter prospective randomized
controlled trial in patients with resected pancreaticobiliary
carcinoma[J]. Cancer, 2002,95(8):1685-1695.
[16]Neoptolemos J P, Moore M J, Cox T F, et al.
Effect of adjuvant chemotherapy with fluorouracil plus
folinic acid or gemcitabine vs observation on survival in
patients with resected periampullary adenocarcinoma: the
ESPAC-3 periampullary cancer randomized trial[J]. JAMA,
2012,308(2):147-156.
[17]Ebata T, Hirano S, Konishi M, et al. Randomized
clinical trial of adjuvant gemcitabine chemotherapy versus
observation in resected bile duct cancer[J]. Br J Surg,
2018,105(3):192-202.
[18]Edeline J, Benabdelghani M, Bertaut A, et al.
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance
in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD
18-UNICANCER GI): A Randomized Phase III Study[J]. J
Clin Oncol, 2019,37(8):658-667.
[19]Verlingue L, Hollebecque A, Boige V, et al.
Matching genomic molecular aberrations with molecular
targeted agents: Are biliary tract cancers an ideal
playground?[J]. Eur J Cancer, 2017,81:161-173.
[20]Primrose J N, Fox R P, Palmer D H, et al.
Capecitabine compared with observation in resected biliary
tract cancer (BILCAP): a randomised, controlled, multicentre,
phase 3 study[J]. Lancet Oncol, 2019,20(5):663-673.
[21]Nakachi K, Ikeda M, Konishi M, et al. Adjuvant
S-1 compared with observation in resected biliary tract
cancer (JCOG1202, ASCOT): a multicentre, openlabel, randomised, controlled, phase 3 trial[J]. Lancet,
2023,401(10372):195-203.
[22 ]Fujiwara Y, Kobaya shi S, Nagano H, et al.
Pharmacokinetic Study of Adjuvant Gemcitabine Therapy
for Biliary Tract Cancer following Major Hepatectomy
(KHBO1101)[J]. PLoS One, 2015,10(12):e0143072.
[23]Kobayashi S, Nakachi K, Ikeda M, et al. Feasibility
of S-1 adjuvant chemotherapy after major hepatectomy
for biliary tract cancers: An exploratory subset analysis of
JCOG1202[J]. Eur J Surg Oncol, 2024,50(2):107324.
[24]Yanagimoto H, Toyokawa H, Sakai D, et al. A
phase I study for adjuvant chemotherapy of gemcitabine plus
S-1 in patients with biliary tract cancer undergoing curative
resection without major hepatectomy (KHBO1202)[J].
Cancer Chemother Pharmacol, 2018,81(3):461-468.
[25]Toyoda M, Ajiki T, Fujiwara Y, et al. Phase I study
of adjuvant chemotherapy with gemcitabine plus cisplatin in
patients with biliary tract cancer undergoing curative resection
without major hepatectomy (KHBO1004)[J]. Cancer
Chemother Pharmacol, 2014,73(6):1295-1301.
[26]Cunningham D, Allum W H, Stenning S P, et al.
Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer[J]. N Engl J Med, 2006,355(1):11-20.
[27]Al-Batran S E, Homann N, Pauligk C, et al.
Perioperative chemotherapy with fluorouracil plus leucovorin,
oxaliplatin, and docetaxel versus fluorouracil or capecitabine
plus cisplatin and epirubicin for locally advanced, resectable
gastric or gastro-oesophageal junction adenocarcinoma
(FLOT4): a randomised, phase 2/3 trial[J]. Lancet,
2019,393(10184):1948-1957.
[28]Goetze T O, Bechstein W O, Bankstahl U S, et al.
Neoadjuvant chemotherapy with gemcitabine plus cisplatin
followed by radical liver resection versus immediate radical
liver resection alone with or without adjuvant chemotherapy
in incidentally detected gallbladder carcinoma after simple
cholecystectomy or in front of radical resection of BTC (ICC/
ECC) - a phase III study of the German registry of incidental
gallbladder carcinoma platform (GR)- the AIO/ CALGP/
ACO- GAIN-trial[J]. BMC Cancer, 2020,20(1):122.
[29]Kobayashi S, Wada H, Sakai D, et al. Impact
of Tumor Shrinkage Pattern with Biweekly Triplet
Gemcitabine+Cisplatin+S-1 Regimen for Biliary Tract
Cancers: Implications for Neoadjuvant Therapy from the
Data of KHBO1401 (KHBO1401-1A Study)[J]. Oncology,
2024,102(6):447-456.
Refbacks
- 当前没有refback。
